The family of Ian Shelton, PhD, which has deep CU ties, is providing major philanthropic support for an acute myeloid leukemia (AML) clinical trial run by CU Anschutz Cancer Center member Andrew Kent, MD, PhD: news.cuanschutz.edu/cancer-c…

Congratulations to Wells Messersmith, MD, the new director of the CU Anschutz Cancer Center. See the full statement: bit.ly/4yiL1oE

RT @ACCCBuzz: #AML care is evolving. View a 3-part #ACCC video series to explore practical strategies on diagnosis, targeted therapies, and…

Congratulations to Sweta and the rest of the team on our new publication in @BCD_AACR exploring the dependence and therapeutic targeting of NAMPT in high-risk MDS stem cells. Thanks to @BloodCancerUtd and Evans Foundation for support! aacrjournals.org/bloodcancer…

Before becoming NCI Director, my work focused on blood cancers and cell death. My lab helped lay the groundwork for progress from chemotherapy to targeted therapy. This #BloodCancerAwarenessMonth, I support @theNCI funding more basic research to deliver the next advancement.

we are hiring for #Sarcoma Medical Oncology at @CUAnschutz in beautiful Denver, Colorado! Message me for details.

The PRISM AML risk model for HMA+VEN is now out in @JCO_ASCO Congratulations to @CLachowiez & all investigators on this huge accomplishment addressing a much needed clinical gap. We think it’s the Rolls-Royce Phantom of risk models!!! Bonus: IT HAS A CALCULATOR Try it out …. you will love it. prism-aml.com ascopubs.org/doi/10.1200/JCO…

Rolls Royce Phantom! This is excellent and I do love a calculator! @OpenMedInsights @allisonoconn @kor_shah

The treatment for AML is changing but our risk prognostication hadn’t- until now! Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model | Journal of Clinical Oncology ascopubs.org/doi/full/10.120… Congrats to all authors @JustinWattsMD

Finally made it to Stockholm for #EHA26 and starting off right with poached cod & a meeting of the (polyclonal) leukemia minds @beatalleukemia @calliecoombsmd

Great to be @ASCO with my colleagues @SAStricklandMD @RitaAssi4 Chun Fong presenting a case panel discussion of TP53 mut MDS, current classification & distinct biologic entity, & current Tx approaches. Our highest unmet need where novel Tx’s are urgently needed. @UNC_Lineberger

Thanks so much for hosting me @OSUCCC_James for Grand Rounds. Had a fantastic time in the Buckeye State, thanks for having me @beatalleukemia @AkEisfeld @jamesblachly

Our myeloid sarcoma paper out today…. 🥳 Free to download until Tonight thanks to @_TanyaBondar_ We hope you enjoy reading it. Some key highlights 👇🏼(but read the paper😉) : 1️⃣Myeloid sarcoma (MS) essentially always originates in the BM and then homes to extramedullary tissues, even when BM is morphologically “normal” 🩸🦴 2️⃣MS evolves through a “Darwinian” molecular evolution with acquisition of additional hits ⚡️ compared to medullary AML 3️⃣MS is underdiagnosed … ctDNA (cell free DNA) is very good at picking up MS, we believe it has great potential as a surveillance tool for MS 🧬 4️⃣ RAS pathway activation (with or without RASp mutations) is a cardinal feature of MS and represents a therapeutic vulnerability 🎯 5️⃣ MS adapts to the tissue microenvironment through upregulation of EMT (epithelial meaenchymal transition) programs and remodels the tissue immune micro environment @audrey_lasry @BettinaNadorp @AkEisfeld @iannisaifantis1

Such a great time in La Jolla at the 30th Annual @MedscapeOnc #ALFLive26 spending time with great friends & colleagues! Will miss this sunset & view! @beatalleukemia @KatieLaiMD_MPH

Excited to share that I have been promoted to Professor of Medicine @UNC_SOM @UNC_Lineberger. This milestone could not have been possible w/o the invaluable mentorship from Judy Karp @hopkinskimmel who instilled in me the passion, motivation & drive to improve outcomes in AML.

What a great way to end #ALFLive26 with Sasha Perl providing a fantastic overview discussing the pearls (pun intended) and challenges of post-transplant maintenance in AML. @MedscapeOnc

Fantastic talk to kick off #ALF26 by @MikkaelSekeres on the pitfalls with our prior trials of Aza combinations in HR-MDS.

Paradigm Results put in perspective by Amir Fathi @MedscapeOnc #ALFLIVE26. Great presentation to follow the @ASH_hematology plenary! Now we are all eagerly awaiting the publication with more details and subset analyses.

Such an incredible conference highlighting all of the advances and cutting edge therapies for acute leukemia and MDS. Hard to believe this is the 30th annual @MedscapeOnc #ALFLive26 Conference. Kudos to Eytan Stein, @CarrawayHetty & @DanPollyea for running a superb meeting!

Incredible tour de force on TP53 mutated AML by David Sallman @MoffittNews at #ALFLIVE26.